Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
RESEARCH TOOLSreports
Holding ITCI?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.07Last Year’s EPS
-$0.3Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 30, 2024
|% Change Since: 8.73%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted robust growth in CAPLYTA sales and a strong financial position, supported by strategic investments in sales force expansion and promising pipeline developments. However, increased expenses and ongoing challenges in developing long-acting injectable formulations were noted as potential concerns.Company Guidance
During the third quarter 2024 earnings call for Intra-Cellular Therapies, the company provided updated guidance and highlighted key performance metrics. CAPLYTA's net sales reached $175.2 million, marking a 39% increase compared to the same quarter in 2023. Driven by strong prescription demand, the company raised its full-year 2024 net sales guidance to a range of $665 million to $685 million. CAPLYTA achieved a 38% year-over-year growth in total prescriptions and a 9% sequential quarter-over-quarter growth rate. The company also expanded its sales force by adding 150 new representatives, aiming to enhance outreach in the primary care market. Additionally, Intra-Cellular Therapies positioned CAPLYTA as a potential $5 billion opportunity within the next decade, supported by the drug's robust efficacy and favorable safety profile in mood disorders, including major depressive disorder (MDD) and bipolar depression. The company continues to advance its pipeline, with significant progress in its lumateperone long-acting injectable and ITI-1284 development programs, targeting generalized anxiety disorder and Alzheimer's disease-related conditions.Record CAPLYTA Sales Growth
CAPLYTA's net sales reached $175.2 million in Q3 2024, marking a 39% increase over Q3 2023, and a 9% sequential growth from Q2 2024.
Increased Full Year Sales Guidance
The company raised its 2024 full-year net sales guidance range to $665 million to $685 million due to continued strong performance.
Expansion of Sales Force
150 new sales representatives were added to focus on primary care physicians, indicating a strategic investment to sustain CAPLYTA's growth.
Promising Pipeline Developments
The company is advancing multiple Phase II and III programs, including ITI-1284 for GAD and psychosis in Alzheimer's, as well as long-acting injectable formulations.
Strong Financial Position
The company reported $1 billion in cash and investments as of September 30, 2024, indicating a robust financial position to support future growth.
---
ITCI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ITCI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $76.75 | $85.47 | +11.36% |
| Aug 07, 2024 | $78.17 | $73.63 | -5.81% |
| May 07, 2024 | $71.01 | $71.21 | +0.28% |
| Feb 22, 2024 | $73.28 | $71.93 | -1.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Intra-Cellular Therapies (ITCI) report earnings?
Intra-Cellular Therapies (ITCI) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Intra-Cellular Therapies (ITCI) earnings time?
Intra-Cellular Therapies (ITCI) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ITCI EPS forecast?
ITCI EPS forecast for the fiscal quarter 2024 (Q4) is -$0.07.
---